COVID-19 mRNA Vaccine and Myocarditis

Balraj Singh; Parminder Kaur; Leon Cedeno; Taulant Brahimi; Prem Patel; Hartaj Virk; Fayez Shamoon; Manesh Bikkina

doi:10.12890/2021_002681

COVID-19 mRNA Vaccine and Myocarditis

Eur J Case Rep Intern Med. 2021 Jun 14;8(7):002681. doi: 10.12890/2021_002681. eCollection 2021.

Authors

Balraj Singh¹, Parminder Kaur², Leon Cedeno³, Taulant Brahimi³, Prem Patel², Hartaj Virk², Fayez Shamoon², Manesh Bikkina²

Affiliations

¹ Department of Hematology-Oncology, Saint Joseph's University Medical Center, Paterson, New Jersey.
² Department of Cardiology, Saint Joseph's University Medical Center, Paterson, New Jersey.
³ Department of Internal Medicine, Saint Joseph's University Medical Center, Paterson, New Jersey.

Abstract

Coronavirus disease 2019 (COVID-19) is believed to have originated in the Hua nan South China Seafood Market in Wuhan and can present with a spectrum of clinical manifestations. We report the case of 24-year-old male patient who developed chest pain after administration of the second dose of the Pfizer-BioNTech mRNA COVID-19 vaccine and who was diagnosed with myocarditis on work-up.

Learning points: Localized injection site reactions and systemic adverse effects can occur after administration of the various COVID-19 vaccines.Healthcare providers should maintain a high index of suspicion regarding myocarditis after mRNA COVID-19 vaccination in the appropriate clinical scenario.

Keywords: COVID-19; COVID-19 vaccine; SARS-CoV-2; adverse events; inflammation of the heart; myocarditis; pericarditis; severe acute respiratory syndrome coronavirus 2; side effects.